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The efficacies of nine enzyme-linked immunOsorbent assays (EIA) for antibody to human Immunodeficiency 
virus type 1 (HIV-I) 8nd one EIA for antibody to HlV-2 Ln detecting antibody to HIV-2 were studied. The 
competitive EIAs for antibody to HIV-I were less selisitive than the indirect E I h .  The overall prevalence of 
positive results was between 28 and 51% with the competitive EIAs and between 70 and 93% with the indirect 
EIAs. Most of the EIAs were less sensitive in detecting antibody to HIV-2 in sera from people with acquired 
immunodeficiency syndrome-like diseases than in sera from symptomless individuals. The results indicate that 
then  is a high degree of cross-reactivity between HIV-1 and HIV-2 by EIA, indicating that serotype specificity 
must be determined by Western blot (immunoblot) with both sets of viral antigens. The results are relevant for 
discussing public health strategies, especially the screening of blood donors; competitive EIAs for antibody to 
HIV-1 are not sensitive enough to be used in areas where HIV-2 is prevalent (West Africa). c 
A category of human retroviruses has been recently 
identified which is related to human immunodeficiency virus 
type 1 (HIV-1) but is more closely related to a group of 
simian retroviruses (STLV3BIV). These viruses, named 
HIV-2, formerly human T cell lymphotropic virus type IV 
(HTLV-IV) or lymphadenopathy-associated virus type 2 
(LAV-2). are prevalent in West Africa and have been found 
occasionally in Europe (1, 4, 6, 9, 10, 11, 13. 18, 19, 21). 
There is a high degree of immunologic cross-reactivity 
between the gag gene products and the pol gene products of 
HIV-1 and HIV-2 (14. 9, 18). In contrast, the envelope 
glycoproteins that are the most frequently detected antigens 
by a9ibodies from exposed individuals are less cross-reac- 
tive. Knowing these cross-reactivities, we evaluated the 
efficacy of 10 enzyme immunoassays (EIAs) for antibody to 
HIV in detecting antibody to HIV-2 in sera from West 
African residents. 
MATERIALS AND METHODS 
Sera. A total of 43 sera matching the original definition of 
sera positive for antibody to HIV-2 were used in this study 
(3.4, 18). All these sera were cbllected in Ivory Coast during 
1986; 23 sera were from symptomless individuals belonging 
to different risk groups, such as  prostituteS. prisoners, or 
individuals suffering from a sexually transmitted disease, 
and 20 sera were from patients with acquired immunodefi- 
ciency syndrome (AIDS)-like diseases. These patients suf- 
fered mainly from a severe respiratory infection associated 
with weight loss (over 10% of body weight) in 18 cases 
(90%). profound asthenia in 18 cases (90%). and persistent 
diarrhea in 9 cases (45%). 
Serotype specificity. Serotype specificity was determined 
by differential reactivity to envelope glycoproteins of HIV-1 
and HIV-2 by using the Western blot (immunoblot) proce- 
dure as already described (3,*4, 18). The Western blot 
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analysis was performed with strips coated with either 
HTLV-IIIB (HIV-1) virions or HTLV-IV,,, (HIV-2) vi- 
nons. Sera that were reactive to gp32 (the transmembrane 
glycoprotein; 16,17) of HTLV-IV,,,, were defined as HIV-2 
antibody positive. Sera that reacted to gp41 of HTLV-IIIB 
were defined as HIV-1 antibody positive and not used in this 
study. 
EIAs. Nine commercial HIV-1 test kits were used (Table 
1). including six indirect EIAs (Abbott Laboratories (first- 
and second-generation tests]; Du Pont Co.; Organon- 
Teknika; Ortho Diagnostics, Inc. ; and Diagnostics Pasteur 
[Elavia 1 with control antigen]); two competitive EIAs 
(Calbiochem-Behring and Wellc6me Diagnostics); and a 
recombinant competitive EIA (Envacore; Abbott) that tests 
for antibody to core or envelope proteins. One commercial 
EIA kit for antibody to. HIV-2 (Elavia 2; Diagnostics Pas- 
teur) was also evaluated. 
RESULTS 
Representative Western blots of typical HIV-2-antibody- 
positive sera are shown in Fig. 1. In addition to the trans- 
membrane glycoprotein gp32, a smearing protein of approx- 
imately 68 kilodaltons resembling a glycoprotein was 
recognized by all the HIV-2-positive sera. This 68-kilodalton 
protein, which appears to be highly immunogenic, remains 
to be identified. 
Sensitivities of the 10 assays in detecting antibody to 
HIV-2 are shown in Table 2. The distribution patterns of 
responses in these EIAs, except for the Envacore from 
Abbott, are represented in Fig. 2. The results indicate that 
the competitive EIAs for HIV-1 were less sensitive than the 
indirect EIAs were in detecting antibody to HIV-2. Of the 43 
HIV-2-positive sera, 12 (28%) and 16 (37%) were positive by 
the Wellcome and Calbiochem-Behring assays, respectively. 
The prevalence of positive sera may be increased to 51% (22 
of 43) with the Calbiochem-Behring assay if a cutoff value 
equal to 0.7N is used (N being the mean absorbance of the 
, -I- 
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TABLE I .  Chiiractcristics of the 10 ElAs 
EIA Principlc Antigen cur or" 
Abboit Laboratories 
1st generation: HTLV-II I Indirect virus N + 0.15P P 
2nd generation: recombiiwnt HTLV-III Indirect Recombinant protein 
Envacorc; core antibody Competition Recombinant protein (P + N)R 
Envacore; envelope antihody Compctition Recombinant protein (P + N)R 
Du Pon! Co. HTLV-III EIJSA" Indirect Virus PI2 
Organon-Teknika Vironostika I nd irrct Virus 0.XN + P) 
034N i P) 
0.3 + N Onho Diagnostics HTLV-I I I ELISA Indirect Virus 
Diagnostics Pasteur 
Elavia 1 
Elavia 2 
Indirect Virus (LAV-1) AOD = 0.3 
Indirect Virus (LAV-2) J O D  = 0.3 
Calbiochem-Behring Enzygnost anti-H IV microdilution Competition Virus 0.5N 
Wellcome Research Lnboriiiorics Wellcozvnie anti-HTLV-Ill CompetiIion Virus P + 10% 
~ ~~ 
" Culolf value calculations arc prcscnlrd us givrir hy thc manuklrrurcr. N. M w n  of ncpalivc controls: P. mean of positive conlrols. 
' JOD. Ch:tngc in oplic~il ilensily. 
ELISA. Enrynlc-linked ininiunosorbenl assay. 
negative controls) as recommended by A. M. CouroucC et al. 
(12). The indirect ElAs for antibody to HIV-1 detected from 
70% (Organon-Teknike) tu 93% (Ortho) of the sera positive 
for antibody to HIV-2. Interestingly, all the ElAs for anti- 
body to HIV-1. exccpt for that from Ortho. were less 
sensitive in detecting iintibodie's to HIV-2 in sera collected 
from sick people (AIDS-like diseases) than in sera collected 
from symptomless individuals (Table 2). For  instance. the 
sensitivity fell from 91%) (21 of 23) in symptomless individ- 
uals to 60% (12 of 20) i n  patients suffering from an AIDS-like 
disease when the first-generation assay from Abbot1 was 
used. Similarly. the sensitivity dropped from 48% (11 of 23) 
to 5% (1 of 20) with the Wellcome assay. 
Of the sera positive for antibody to HIV-2,77% (33 of 43) 
and 56% (24 of 43) were positive for antibody to HIV-I core 
proteins and for antibody to HIV-1 envelope proteins. re- 
speclively, by the Envacore assay (Table 2). A total of 20 
HIV-2-positive sera (47%) were positive for both envelope 
and core recombinant proteins of HIV-1 (Fig. 3). and 13 
(30%) were positive only for antibody to HIV-1 core recom- 
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FIG. 1. Reprcsen1ative strips of Western blot assays against HIV-1 (lanes a) and HIV-2 (lanes b). Panels: 1. sera positive for antibody 10 
HIV.1; 2 to 9, sera positive for antibody to HIV-2. The molecular sizes of the proteins fin kilodaltons) are indicated for HIV-1 (left side) and 
HIV-2 (right side). 
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binant protein. Four sera (9%) were positive only for anti- 
body to HIV-I envelopc recombinant protein. This assay 
was also less sensitive in detecting cross-rcacting antibodies 
in sera from patients with AIDS-like discases than in sera 
from symptomless individuals (Table 2). 
The Elavia 2 assay that uses LAV-2 as the viral antigen 
detected 98% (42 of 43) of sera positive for antibody to 
HIV-2. One serum collected from a sick person was found 
repeatedly negative (absorbance value cutoff, 0.8). This 
serum contained only antibody to HIV-2 glycoproteins (Fig. 
1, lane 6). However, it was weakly positive in seven of the 
nine ElAs for antibody to HIV-I. 
DISCUSSION. 
This study shows that commercial HIV-1 antibody test 
kits are not equally efficient in detecting HIV-2-antibody- 
positive sera. Particularly, competitive ElAs are less sensi- 
tive than indirect EIAs. This conclusion confirms prelimi- 
nary observations (7. 14) which indicated that cross-reacting 
HIV-2 antibodies do  not have enough affinity to compete 
with the anti-HIV-1 conjugate. HIV-2-positive AIDS pa- 
tients were reported not to have serological cross-reactivity 
which HIV-1 (8, 9). This is not confirmed by the present 
extensit:e study. Our study indicates that the indirect ElAs 
for antibody to HIV-1 detected from 50% (Organon-Teknika) 
to 95% (Ortho) of HIV-2-antibody-positive sera collected 
from patients with AIDS-like diseases. The competitive 
EIAs detected only from 5% (Wellcome) to 20 to 40% 
(Calbiochem-Behring) of the same HIV-2-antibody-positive 
sera. However, it is clear that most of the EIAs for antibody 
to HIV-1 were less sensitive in detecting antibody to HIV-2 
in sera collected from sick people than in sera collected from 
TABLE 2. Efficacies of the 10 ElAs in detecting antibody 
to HIV-2 in 43 positive sera 
No. (W) of 
positive results in no, 
individuals with: of 
results EIA NO AIDS-like = 4.1) 
symptoms diseases 
0 1  = 20) ( n  = 23) 
Abbail Laboratories 
1st generation 21 (91) 
2nd generation 21 (91) 
Core antibody 21 (91) 
Envelope antibody 14 (61) 
Core + envelope antibodies 22 (96) 
Du Pont Co. 22 (96) 
Organon-Te knika 
O.S(N + P) 17 (74) 
0.2(4N + P) 19 (83) 
Ortho Diagnostics 21 (91) 
Diagnostics Pasteur 
Elavia 1 18 (78) 
Elavia 2 23 (100) 
Calbiochem-Behring 
OSN 12 (52) 
0.7N 14 (61) 
Wellcome Research 11 (48) 
taboralorics 
12 (SO) 
13 (65)  
12 (60) 
10 (50) 
15 (75) 
16 (80) 
5 (25) 
1 1  (55 )  
19 (95) 
13 (65) 
19 (95) 
4 (20) 
8 (40) 
l ( 5 )  
33 (77) 
34 (79) 
.33 (77) 
24 (56) 
37 (86) 
38 (RU) 
2' (51) 
30 (70) 
40 (93) 
32 (74) 
42 (9R) 
16 (37) 
22 (S1) 
12 (28) 
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FIG. 2. Distribution paltcrns of responses in the ElAs for 43 yrd 
posilive for antibody to HIV-2. Results arc expressed as the ratios of 
optical density to cutoff value, except for the Calbiochem-Behring 
and Wellcome assays, for which results arc expressed as the ratios 
of cutoff value to opticiil density. . 
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FIG. 3. Distribution of competition values obtained in the 
recombinant competilive EIA that tests for antibody to core Or 
envelope proteins of HIV-1 (Envacorc). Results are expressed as 
percentages of competition calculated as follows: 96 competition = 
(1 - [(A - P)/(N - P)]] x 100. with A bring the sample absorbance 
value. P being lhe positive control mean absorbance value. and N 
being the negative control mean absorbance value. Samples with 
competition values above 50% were considered positive. Symbols: 
A. symptomless individuals: O. patients with AIDS-like diseases. 
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symptomless ind iv iua ls .  This may bc ascribable to low 
antibody titers or t o  a n  absence of antibody t o  the core 
proteins that are also common in patients with HIV-1- 
associated AIDS (5. 211. the disappearance or absence of 
antibody t o  the core proteins of HIV-2 reflecting a lack of  
major cross-reacting antibodies. 
It has  been shown b j  radioimmunoprccipitation and so- 
dium dodecyl sulfate-polyacrylamide pel electrophoresis 
(RIP/SDS-PAGE) that HI V-1 and  HIV-2 share epitopes in all 
the major viral antigens (18). The  cross-reactivity is promi- 
nent for the gng-encodcd proteins, but i t  must be noted that 
some human sera may rccognizc both envelope glycopro- 
teins with diflerential cfficacy on  the basis of RIPISDS- 
PAGE analyses. In thc  present study, w e  demonstrate that 
56% of people exposed to HIV-2 developed antibodies that 
cross-reacted with a recombinant-DNA-derived HIV-1 anti- 
gen from the c m  region containing all aniino acids of gp41 a s  
well as a portion of g p l l 0 .  This  indicatcs that the Envacore 
assay did not allow a scrotype-specific diagnosis based on 
the  recombinant envelopc protein of HIV- l .  This observa- 
tion has important impliìations. First, i t  confirms that anti- 
gens encoded by the w v  genes of HIV-1 and HIV-2 are 
serologically cross-reaclive when nondenatured proteins, 
even  those produced by recombinant technology. are used. 
Further characterization of  these cross-reactive epilopes in 
the  cnv-encoded proteins may be important for evaluation as 
subunits for  a n  AIDS vaccine. Second, care should be taken 
in interpreting serological diagnosis of HIV infections. A 
sensitive assay able to  discriminate between antibodies t o  
HIV-1 envelope proteins and HIV-2 envelope proteins must 
be used. In  this respect. Western blot seems to  be very 
useful; antibody-positive sera give a strong signal with the 
transmembrane g lycopo te in  of the corresponding serotype 
alone. RIPISDS-PAGE is more able to detect cross-reactive 
antibodies t o  the em-encoded gp120 and gp160 (18). indicat- 
ing that epitopes associ:ited with the primary structure of the 
transmembrane proteins a re  weakly conserved if a t  all 
between HIV-1 and HIV-2. However.  some amino acid 
resUÚes important for the  secondary and tertiary structures 
of the  envelope proteins are conserved. Therefore, common 
or cross-reactive conformational epilopes, detecled by 
RIPISDS-PAGE but not by  Western blot, are conserved; 
they are present in etri. gene products of both viruses (16. 
17). It has been shown recently that it i s  possible to discrim- 
inate between antibodies to  HIV-1 and antibodies to  HIV-2 
by using synthetic peptides located within the transmem- 
brane glycoproteins of these  related viruses (15, 20, 22). 
These  studies suggest that  peptides of both conserved and 
nonconserved epitopes of t he  envelope glycoproteins of 
related HTLVs  may be useful for specific diagnostic pur- 
poses. 
Our  study presents da ta  on the e f icacy  of  10 ElAs  in 
detecting antibody to  HIV-2. The  results indicate that com- 
petitive EIAs for antibody to HIV-1 arc  not sensitive enough 
to  be used in areas whcre  HIV-2 is prevalent (West Africa). 
In  these areas,  serotype specificity must be determined by 
immunoblot with both sets of  viral antigens whether an 
indirect EIA for HIV-1 or for HIV-2 is used as a scrccning 
procedure. 
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